S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:AVXL - Anavex Life Sciences Stock Price, Forecast & News

$2.44
+0.08 (+3.39 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$2.30
Now: $2.44
$2.58
50-Day Range
$2.31
MA: $2.55
$3.02
52-Week Range
$1.25
Now: $2.44
$4.09
Volume843,339 shs
Average Volume410,089 shs
Market Capitalization$128.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.16
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AVXL
CUSIPN/A
Phone844-689-3939

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.45 per share

Profitability

Net Income$-17,450,000.00

Miscellaneous

Employees13
Market Cap$128.47 million
Next Earnings Date12/16/2019 (Confirmed)
OptionableOptionable

Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.


Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences Corp (NASDAQ:AVXL) posted its quarterly earnings results on Wednesday, December, 12th. The biotechnology company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.02. View Anavex Life Sciences' Earnings History.

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, December 16th 2019. View Earnings Estimates for Anavex Life Sciences.

How can I listen to Anavex Life Sciences' earnings call?

Anavex Life Sciences will be holding an earnings conference call on Monday, December 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for AVXL?

4 brokerages have issued 12 month price targets for Anavex Life Sciences' stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate Anavex Life Sciences' stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 340.6% from the stock's current price. View Analyst Price Targets for Anavex Life Sciences.

What is the consensus analysts' recommendation for Anavex Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Anavex Life Sciences.

Has Anavex Life Sciences been receiving favorable news coverage?

News stories about AVXL stock have been trending extremely negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anavex Life Sciences earned a news impact score of -4.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the stock's share price in the next several days. View News Stories for Anavex Life Sciences.

Are investors shorting Anavex Life Sciences?

Anavex Life Sciences saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 6,320,000 shares, a decline of 6.0% from the October 31st total of 6,720,000 shares. Based on an average trading volume of 319,600 shares, the short-interest ratio is presently 19.8 days. Approximately 12.6% of the company's shares are short sold. View Anavex Life Sciences' Current Options Chain.

Who are some of Anavex Life Sciences' key competitors?

What other stocks do shareholders of Anavex Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), CytRx (CYTR), Brainstorm Cell Therapeutics (BCLI), Sanchez Energy (SN), VASCO Data Security International (VDSI), Arch Therapeutics (ARTH), Novavax (NVAX), Energous (WATT) and Geron (GERN).

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the folowing people:
  • Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 53)
  • Ms. Sandra Boenisch, Principal Financial Officer & Treasurer (Age 38)
  • Mr. Stephan Toutain, Sr. VP of Operations (Age 53)
  • Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory Affairs
  • Dr. Walter E. Kaufmann, Chief Medical Officer

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (1.49%), Hikari Power Ltd (0.89%), Virtu Financial LLC (0.10%), AllSquare Wealth Management LLC (0.08%), Commonwealth Equity Services LLC (0.05%) and Foster Victor Wealth Advisors LLC (0.05%). View Institutional Ownership Trends for Anavex Life Sciences.

Which major investors are selling Anavex Life Sciences stock?

AVXL stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Anavex Life Sciences.

Which major investors are buying Anavex Life Sciences stock?

AVXL stock was acquired by a variety of institutional investors in the last quarter, including Hikari Power Ltd, State Street Corp, Virtu Financial LLC, Foster Victor Wealth Advisors LLC, Kessler Investment Group LLC, FormulaFolio Investments LLC, Squarepoint Ops LLC and Commonwealth Equity Services LLC. View Insider Buying and Selling for Anavex Life Sciences.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $2.44.

How big of a company is Anavex Life Sciences?

Anavex Life Sciences has a market capitalization of $128.47 million. The biotechnology company earns $-17,450,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Anavex Life Sciences employs 13 workers across the globe.View Additional Information About Anavex Life Sciences.

What is Anavex Life Sciences' official website?

The official website for Anavex Life Sciences is http://www.anavex.com/.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]


MarketBeat Community Rating for Anavex Life Sciences (NASDAQ AVXL)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe AVXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel